[go: up one dir, main page]

WO2008145689A1 - H-fabp utilisée comme prédicteur précoce de l'infarctus du myocarde - Google Patents

H-fabp utilisée comme prédicteur précoce de l'infarctus du myocarde Download PDF

Info

Publication number
WO2008145689A1
WO2008145689A1 PCT/EP2008/056603 EP2008056603W WO2008145689A1 WO 2008145689 A1 WO2008145689 A1 WO 2008145689A1 EP 2008056603 W EP2008056603 W EP 2008056603W WO 2008145689 A1 WO2008145689 A1 WO 2008145689A1
Authority
WO
WIPO (PCT)
Prior art keywords
amount
fabp
myoglobin
subject
myocardial infarction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/056603
Other languages
English (en)
Inventor
Georg Hess
Hendrik Hüdig
Rosemarie Kientsch-Engel
Dietmar Zdunek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Original Assignee
F Hoffmann La Roche AG
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07109141A external-priority patent/EP1998178A1/fr
Application filed by F Hoffmann La Roche AG, Roche Diagnostics GmbH filed Critical F Hoffmann La Roche AG
Priority to EP08760194A priority Critical patent/EP2167975A1/fr
Priority to JP2010509821A priority patent/JP2010528306A/ja
Publication of WO2008145689A1 publication Critical patent/WO2008145689A1/fr
Priority to US12/623,495 priority patent/US8062857B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction

Definitions

  • H-FABP Heart-type fatty acid binding protein
  • a variant as referred to in accordance with the present invention shall have an amino acid sequence which differs due to at least one amino acid substitution, deletion and/or addition wherein the amino acid sequence of the variant is still, preferably, at least 50%, 60%, 70%, 80%, 85%, 90%, 92%, 95%, 97%, 98%, or 99% identical with the amino sequence of the specific Troponin.
  • Variants may be allelic variants or any other species specific homologs, paralogs, or orthologs.
  • the variants referred to herein include fragments of the specific cardiac Troponins or the aforementioned types of variants as long as these fragments have the essential immunological and biological properties as referred to above. Such fragments may be, e.g., degradation products of the Troponins. Further included are variants which differ due to posttranslational modifications such as phosphorylation or myristylation.
  • the Troponin level in a subject who suffers from acute coronary syndrome and has a cardiac Troponin level which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction (as defined in this application) ranges from 0.002 to 0.1 ng/ml (equal or larger than 0.002, but lower than 0.1 ng/ml).
  • variants referred to above may be allelic variants or any other species specific homo logs, paralogs, or orthologs.
  • variants referred to herein include fragments of the specific H-FABP and myoglobin polypeptides, respectively or the aforementioned types of variants as long as these fragments have the essential immunological and biological properties as referred to above.
  • fragments may be, e.g., degradation products of the H-FABP and myoglobin polypeptides, respectively.
  • variants which differ due to posttranslational modifications such as phosphorylation or myristylation.
  • the value of the determined amount may be compared to values corresponding to suitable references which are stored in a database by a computer program.
  • the computer program may further evaluate the result of the comparison, i.e. automatically provide the desired assessment in a suitable output format. Based on the comparison of the amount(s) determined in step a) to suitable reference amount(s), it is possible to diagnose MI in said subject. It is to be understood that an amount of H-FABP as determined in step (a) of the methods of the presents invention is compared in step (b) to a reference amount for H-FABP as specified elsewhere in this application and that an amount of myoglobin is compared to a reference amount for myoglobin.
  • kit refers to a collection of the aforementioned means, preferably, provided separately or within a single container.
  • the kit may in addition comprise means for determining the amount of a cardiac Troponin.
  • the kit may additionally comprise a user's manual for interpreting the results of any measurement(s) with respect to diagnosing MI in a subject as defined in the present invention.
  • a user's manual may include information about what determined amounts corresponds to what kind of diagnosis. This is outlined in detail elsewhere in this specification. Additionally, such user's manual may provide instructions about correctly using the components of the kit for determining the amount of the respective biomarkers.
  • FIG. 2 Receiver operating characteristic (ROC) curve for myoglobin.
  • ROC curve analysis was done to determine diagnostic accuracy by calculation of diagnostic sensitivity vs. (1 -specificity) for a given diagnostic parameter (myoglobin) according clinical outcome (Non-Myocardial Infarction (M ⁇ )-Converter vs. Myocardial Infarction (M ⁇ )-Converter). Included in this ROC curve are the data obtained for patients with stable coronary heart disease and ACS (see Examples). The cut-off score for the clinical outcome MI is 61 ng/ml myoglobin.
  • ROC-AUC Receiver operating characteristic-area under curve; C. O. cut-off).
  • a Troponin T level of larger than 0.1 ng/ml in a sample that was obtained at least 6 hours after the onset of symptoms was considered as being indicative for the recent occurence MI (Mi-converter), otherwise UAP was diagnosed (Non-MI-converter).

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne un procédé qui permet de diagnostiquer l'infarctus du myocarde chez un sujet souffrant d'un syndrome coronaire aigu et possédant un niveau de troponine cardiaque détectable, mais inférieur au niveau considéré comme indicatif d'un infarctus du myocarde. L'invention se rapporte en outre à un procédé qui permet d'identifier un sujet comme étant susceptible de subir une intervention cardiaque, le sujet souffrant d'un syndrome coronaire aigu et possédant un niveau de troponine cardiaque détectable, mais inférieur au niveau considéré comme indicatif d'un infarctus du myocarde. Les procédés de l'invention reposent sur une mesure de la H-FABP et, facultativement, de la myoglobine dans un échantillon dudit sujet, et sur une comparaison entre la quantité de H-FABP et, facultativement, de la myoglobine, et des quantités de référence. L'invention se rapporte également à des trousses ou dispositifs destinés à la mise en oeuvre de l'invention.
PCT/EP2008/056603 2007-05-29 2008-05-29 H-fabp utilisée comme prédicteur précoce de l'infarctus du myocarde Ceased WO2008145689A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP08760194A EP2167975A1 (fr) 2007-05-29 2008-05-29 H-fabp utilisée comme prédicteur précoce de l'infarctus du myocarde
JP2010509821A JP2010528306A (ja) 2007-05-29 2008-05-29 心筋梗塞の早期予測因子としてのｈ−ｆａｂｐ
US12/623,495 US8062857B1 (en) 2007-05-29 2009-11-23 H-FABP as early predictor of myocardial infarction

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07109141.7 2007-05-29
EP07109141A EP1998178A1 (fr) 2007-05-29 2007-05-29 H-FABP en tant que prédicateur précoce d'infarctus du myocarde
EP07116337 2007-09-13
EP07116337.2 2007-09-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/623,495 Continuation US8062857B1 (en) 2007-05-29 2009-11-23 H-FABP as early predictor of myocardial infarction

Publications (1)

Publication Number Publication Date
WO2008145689A1 true WO2008145689A1 (fr) 2008-12-04

Family

ID=39591458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056603 Ceased WO2008145689A1 (fr) 2007-05-29 2008-05-29 H-fabp utilisée comme prédicteur précoce de l'infarctus du myocarde

Country Status (3)

Country Link
EP (1) EP2167975A1 (fr)
JP (1) JP2010528306A (fr)
WO (1) WO2008145689A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064358A1 (fr) 2009-11-27 2011-06-03 Roche Diagnostics Gmbh Procédé pour diagnostiquer et contrôler une ischémie cardiaque chez des patients avec une douleur aiguë da la poitrine et sans infarctus du myocarde
WO2012028713A1 (fr) 2010-09-02 2012-03-08 Roche Diagnostics Gmbh Méthode de diagnostic et de surveillance de l'état pathophysiologique cardiaque chez un sujet subissant ou ayant subi une intervention coronarienne percutanée (pci)
EP2687853A1 (fr) * 2012-06-22 2014-01-22 Randox Laboratories Ltd. Combinaison d'exclusion précoce de l'infarctus aigu du myocarde

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL245091B (en) * 2016-04-13 2020-02-27 Novamed Ltd Single stage cardiac test device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6099469A (en) * 1998-06-02 2000-08-08 Armstrong; E. Glenn Reflex algorithm for early and cost effective diagnosis of myocardial infractions suitable for automated diagnostic platforms
US6443889B1 (en) * 2000-02-10 2002-09-03 Torgny Groth Provision of decision support for acute myocardial infarction
US20050014198A1 (en) * 2002-07-11 2005-01-20 Leong Ng Assays and kits for detecting and monitoring heart disease

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
ISHII JUNNICHI ET AL: "Prognostic value of serum concentration of heart-type fatty acid-binding protein relative to cardiac troponin T on admission in the early hours of acute coronary syndrome", CLINICAL CHEMISTRY, vol. 51, no. 8, August 2005 (2005-08-01), pages 1397 - 1404, XP002454289, ISSN: 0009-9147 *
LEFÈVRE G ET AL: "[Multicenter evaluation of h-FABP semi-quantitative assay (Cardio Detect) in central laboratory: the point in acute myocardial infarction diagnosis]", ANNALES DE BIOLOGIE CLINIQUE 2007 JUL-AUG, vol. 65, no. 4, July 2007 (2007-07-01), pages 377 - 384, XP009090494, ISSN: 0003-3898 *
MORROW DAVID A ET AL: "Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: Results from a randomized trial", JAMA (JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION), vol. 286, no. 19, 21 November 2001 (2001-11-21), pages 2405 - 2412, XP002454292, ISSN: 0098-7484 *
SEINO YOSHIHIKO ET AL: "Use of a whole blood rapid panel test for heart-type fatty acid-binding protein in patients with acute chest pain: Comparison with rapid troponin T and myoglobin tests.", AMERICAN JOURNAL OF MEDICINE, vol. 115, no. 3, 15 August 2003 (2003-08-15), pages 185 - 190, XP002454291, ISSN: 0002-9343 *
SUZUKI MASARU ET AL: "Prognostic value of a qualitative test for heart-type fatty acid-binding protein in patients with acute coronary syndrome.", INTERNATIONAL HEART JOURNAL JUL 2005, vol. 46, no. 4, July 2005 (2005-07-01), pages 601 - 606, XP002454290, ISSN: 1349-2365 *
TANAKA K ET AL: "SERUM AND URINARY HUMAN HEART FATTY ACID-BINDING PROTEIN IN ACUTE MYOCARDIAL INFARCTION", CLINICAL BIOCHEMISTRY, PERGAMON PRESS, vol. 24, 1991, pages 195 - 201, XP009006054, ISSN: 0009-9120 *
WATANABE TOSHIO ET AL: "Development of a simple whole blood panel test for detection of human heart-type fatty acid-binding protein", CLINICAL BIOCHEMISTRY, PERGAMON PRESS, vol. 34, no. 4, June 2001 (2001-06-01), pages 257 - 263, XP002256862, ISSN: 0009-9120 *
WILL K ET AL: "ONE-STEP ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA) FOR PLASMA FATTY ACID-BINDING PROTEIN", ANNALS OF CLINICAL BIOCHEMISTRY, BRITISH MEDICAL ASSOCIATION, LONDON, GB, vol. 34, no. 3, 1997, pages 263 - 268, XP008023075, ISSN: 0004-5632 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011064358A1 (fr) 2009-11-27 2011-06-03 Roche Diagnostics Gmbh Procédé pour diagnostiquer et contrôler une ischémie cardiaque chez des patients avec une douleur aiguë da la poitrine et sans infarctus du myocarde
US8663941B2 (en) 2009-11-27 2014-03-04 Roche Diagnostics Operations, Inc. Method for diagnosing and monitoring cardiac ischemia in patients with acute chest pain and without myocardial infarction
WO2012028713A1 (fr) 2010-09-02 2012-03-08 Roche Diagnostics Gmbh Méthode de diagnostic et de surveillance de l'état pathophysiologique cardiaque chez un sujet subissant ou ayant subi une intervention coronarienne percutanée (pci)
EP2687853A1 (fr) * 2012-06-22 2014-01-22 Randox Laboratories Ltd. Combinaison d'exclusion précoce de l'infarctus aigu du myocarde

Also Published As

Publication number Publication date
JP2010528306A (ja) 2010-08-19
EP2167975A1 (fr) 2010-03-31

Similar Documents

Publication Publication Date Title
US8062857B1 (en) H-FABP as early predictor of myocardial infarction
JP5309026B2 (ja) Ｇｄｆ−１５に基づく心臓インターベンションの危険性を評価するための手段および方法
JP4944185B2 (ja) 症状のある患者における急性および慢性の心筋壊死の区別のための手段と方法
CA2778873C (fr) Methode de determination du risque de blessure chronique pendant ou immediatement apres une chirurgie
EP2279419A1 (fr) Facteur gdf-15 utilisé comme biomarqueur dans le diabète de type 1
CN101126756A (zh) 心脏肌钙蛋白作为晚期冠状动脉疾病及其并发症的指示物
WO2009047285A1 (fr) Rapport de peptide natriurétique/troponine servant à l'évaluation d'un dysfonctionnement myocardique préexistant chez des patients atteints du syndrome coronaire aigu
EP2769227B1 (fr) Diagnostic de patients à risque et de cause d'accident vasculaire cérébral fondé sur les peptides bnp et la troponine
CA2601147A1 (fr) Marqueurs biochimiques pour l'embolie pulmonaire aigue
US20110082349A1 (en) Means and methods for determining the arteriosclerotic stenosis using inflammatory biomarkers
WO2008145689A1 (fr) H-fabp utilisée comme prédicteur précoce de l'infarctus du myocarde
US7977105B2 (en) Myoglobin as early predictor of myocardial infarction
EP1925943A1 (fr) Moyens et procédés pour l'optimisation de la diagnose et de la thérapie pour les artériopathies chroniques basés sur la détection de la troponin T et la NT-proBNP.
US20100273268A1 (en) Determining atherosclerotic load using placental growth factor
US8440463B2 (en) Predicting renal failure in diabetes patients based on placental growth factor and soluble FLT-1
EP2037278A1 (fr) Marqueurs vasculaires pour le remodelage d'une lésion cardiaque
WO2010018123A1 (fr) Protéine 4 liant le rétinol utilisée en tant que marqueur d'insulinorésistance périphérique dans le diabète de type 1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760194

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2010509821

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008760194

Country of ref document: EP

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)